A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Public ClinicalTrials.gov record NCT02551874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.
Study identification
- NCT ID
- NCT02551874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 650 participants
Conditions and interventions
Conditions
Interventions
- Saxagliptin, Onglyza Drug
- Dapagliflozin, Farxiga Drug
- Glargine insulin Drug
- Metformin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2015 (Actual)
- Primary completion
- May 8, 2017 (Actual)
- Completion
- Nov 10, 2017 (Actual)
- Last update posted
- Dec 11, 2018
2015 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Los Angeles | California | 90057 | — |
| Research Site | Miami | Florida | 33144 | — |
| Research Site | Miami | Florida | 33155 | — |
| Research Site | St. Petersburg | Florida | 33709 | — |
| Research Site | Norcross | Georgia | 30071 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Lexington | Kentucky | 40502 | — |
| Research Site | Quincy | Massachusetts | 02169 | — |
| Research Site | Beavercreek | Ohio | 45432 | — |
| Research Site | Norman | Oklahoma | 73069 | — |
| Research Site | Barto | Pennsylvania | 19504 | — |
| Research Site | Columbia | South Carolina | 29204 | — |
| Research Site | Bristol | Tennessee | 37620 | — |
| Research Site | Kingsport | Tennessee | 37660 | — |
| Research Site | Houston | Texas | 77004 | — |
| Research Site | Mesquite | Texas | 74194 | — |
| Research Site | San Antonio | Texas | 78230 | — |
| Research Site | San Antonio | Texas | 78258 | — |
| Research Site | Bountiful | Utah | 84010 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02551874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2018 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02551874 live on ClinicalTrials.gov.